Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vanguard Mega Cap Growth ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $302.69 (market cap $14.23B), while Vanguard Mega Cap Growth ETF trades at $94.45 (market cap $33.70B). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 2.4× Charles River Laboratories Intl. Inc's market cap, and Vanguard Mega Cap Growth ETF is more actively traded (1,362,010 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Vanguard Mega Cap Growth ETF for 45 Days on average.
| CRL | MGK | |
|---|---|---|
Market Cap | $14.23B | $33.70B |
Volume | 1,176,885 | 1,362,010 |
Sector | Health | Broad Market / Factor |
52-Week High | $310.77 | $95.11 |
52-Week Low | $149.93 | $70.70 |
Typical Hold Time | 33 Days | 45 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
MGK trades at $94.92, down 0.2% on the day, with a bullish technical signal from moving averages but bearish momentum from oscillators. The ETF focuses on large-cap US growth stocks with heavy technology concentration, offering low 0.05% expense ratio exposure to companies like Nvidia, Apple, and Microsoft. Recent articles highlight its strong five-year performance and appeal for long-term growth investors seeking mega-cap stability.
MGK presents a compelling growth ETF option with concentrated mega-cap exposure, though its tech-heavy composition increases sector-specific risk. The fund's low costs and historical outperformance make it suitable for investors with higher risk tolerance, while current technical indicators suggest potential near-term consolidation after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
